CHANGZHOU PHARM
GenericsCHANGZHOU PHARM is a generic drug manufacturer focused on Cardiovascular, Infectious Disease.
CHANGZHOU PHARM's Key Drugs
CHANGZHOU PHARM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
CHANGZHOU PHARM's Recent FDA Approvals
New NDA/BLA approvals for CHANGZHOU PHARM over the last two years — novel drugs only, excluding generics and label supplements.
CHANGZHOU PHARM's Therapeutic Areas
CHANGZHOU PHARM's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CHANGZHOU PHARM's Top Competitors
CHANGZHOU PHARM's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CHANGZHOU PHARM Pipeline Snapshot
Active clinical trials for CHANGZHOU PHARM across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2016-10-31
- Latest
- 2026-02-02
- Applications
- 5